Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.75 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.75 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.58 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.55 |
| ▸ | IL1B | P01584 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22500886 | 1.00 | CRBN (0.75) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL21062689 | 1.00 | CRBN (0.75) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL24621026 | 0.96 | CRBN (0.75) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL24621039 | 0.95 | CRBN (0.77) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL21224312 | 0.94 | DDB1 (0.81) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL30850474 | 0.93 | CRBN (0.82) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL30850416 | 0.93 | CRBN (0.82) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL30087485 | 0.92 | CRBN (0.74) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL29645873 | 0.92 | CRBN (0.74) | CRBNDDB1MAP1LC3BSTAT3TNF | |
| SCHEMBL30850501 | 0.91 | CRBN (0.83) | CRBNDDB1MAP1LC3BSTAT3TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-04-29 | — | — | US | disclosed |
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-11-07 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| EP-4168441-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| US-11633490-B2 | — | — | 2023-04-25 | — | — | US | disclosed |
| WO-2023019166-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC (US) | 2023-02-16 | — | — | WO | disclosed |
| US-20220072142-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2022-03-10 | — | — | US | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021257650-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3706736-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | The Regents of the University of Michigan (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366774-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | CRBN 12/4885DDB1 807/4885MAP1LC3B 379/4885 |
| US-11110177-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CRBN 12/4885DDB1 807/4885MAP1LC3B 379/4885 |
| US-20190142961-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWITH | ASH1L, ASH2L, DOT1L | CRBN 12/4885DDB1 807/4885MAP1LC3B 379/4885 |
| US-20230226195-A1 | TARGETED ABERRANT ALPHA-SYNUCLEIN SPECIES AND INDUCED UBIQUITINATION AND PROTEOSOMAL CLEARANCE VIA CO-RECRUITMENT OF AN E3-LIGASE SYSTEM | SNCA, ADRM1, UBE3C | CRBN 139/4885DDB1 557/4885MAP1LC3B 178/4885 |
| US-11786602-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CRBN 12/4885DDB1 807/4885MAP1LC3B 379/4885 |
| US-20220072142-A1 | ASH1L DEGRADERS AND METHODS OF TREATMENT THEREWIT | ASH1L, ASH2L, CHD1L | CRBN 20/4885DDB1 844/4885MAP1LC3B 396/4885 |
| US-12285490-B2 | ASH1L degraders and methods of treatment therewith | ASH1L, ASH2L, DOT1L | CRBN 12/4885DDB1 807/4885MAP1LC3B 379/4885 |
| US-11633490-B2 | — | ASH1L, ASH2L, STUB1 | CRBN 9/4885DDB1 611/4885MAP1LC3B 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.